Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
GlobeNewswire
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company..
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company..
NEW YORK--(BUSINESS WIRE)--Ted Pick, Chief Executive Officer of Morgan Stanley, will speak at the Morgan Stanley Annual U.S...
*LOS ANGELES, CA / ACCESSWIRE / May 20, 2024 / *The Schall Law Firm, a national shareholder rights litigation firm, announces that..